Saha T, Mondal J, Khiste S, Lusic H, Hu Z, Jayabalan R, Hodgetts K, Jang H, Sengupta S, Lee SE, Park YG, Lee LP, Goldman A* Nanotherapeutic approaches to overcome distinct drug resistance barriers in models of breast cancer. Nanophotonics. Accepted June 2021. Ahead of Print. DOI:10.1515/nanoph-2021-0142

Przedborski M, Smalley M, Thiyagarajan S, Goldman A, Kohandel M. Systems biology informed neural networks (SBINN) predict response and novel combinations for PD-1 checkpoint blockade. Communications Biology (Nature Press). Provisionally Accepted. June, 2021.

Jenner A, Smalley M, Goldman D, Goins WF, Cobbs CS, Puchalski RB, Chiocca EA, Lawler S, Macklin P, Goldman A, Craig M. Stromal densityshapes the response to HSV-1 oncolytic virus rQNestinin brain tumours. J. for Immuno. of Cancer (JITC). Provisionally Accepted. May, 2021.

Craig M, Jenner AL, Namgung B, Lee LP, Aaron Goldman*. Engineering in Medicine to Address the Challenge of Cancer Drug Resistance: From Micro- and Nanotechnologies to Computational and Mathematical Modeling. ACS Chemical Reviews. Volume 121, Issue 6, March 24, 2021. *Corresponding author




Smalley M, Natarajan SK, Mondal J, Goldman D, Shanthappa B, Pellowe M, Dash C, Saha T, Khiste S, Ramadurai N, Eton EO, Smalley JL, Brown A, Thayakumar A, Rahman M, Arai K, Kohandel M, Sengupta S, Goldman A.* Nano-Engineered Disruption of Heat shock protein 90 (Hsp90) Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer. Cancer Research. 2020 Oct 19:canres.4036.2019. doi: 10.1158/0008-5472.CAN-19-4036. Online ahead of print. *Corresponding author

Smalley, M., Przedborski, M., Thiyagaragan, S., Pellowe, M., Verma, A.,Brijwani, N., Datta, D., Jain, M., Shanthappa, B.U, Kapoor, V., Gopinath, K.S., Doval, D.C., Sabitha,K.S., Taroncher-Oldenburg, G., Majumder, B., Majumder, P., Kohandel, M., Goldman, A.*, Integrating systems biology and an ex vivo human tumor model elucidates PD-1 blockade response dynamics, iSCIENCE (Cell Press). 2020 Jun 26;23(6):101229. doi: 10.1016/j.isci.2020.101229. Epub 2020 Jun 2.*Corresponding author




Goldman A*, Smalley JL, Mistry M, Krenzlin H, Zhang H, Dhawan A, Caldarone B, Moss SJ, Silbersweig DA, Lawler SE, Braun IM. A computationally inspired in-vivo approach identifies a link between amygdalar transcriptional heterogeneity, socialization and anxiety. Transl Psychiatry. 2019 Dec 9;9(1):336. doi: 10.1038/s41398-019-0677-1. *Corresponding author.

Craig M, Kaveh K, Woosley A, Brown AS, Goldman D, Eton E, Mehta RM, Dhawan A, Arai K, Rahman MM, Chen S, Nowak MA, Goldman A*. Cooperative Adaptation to Therapy (CAT) Confers Resistance in Heterogeneous Non-Small Cell Lung Cancers. PLoS Comput Biol. 2019 Aug 26;15(8):e1007278. doi: 10.1371/journal.pcbi.1007278. eCollection 2019 Aug. *Corresponding author. ISSUE COVER

Goldman A*, Khiste S, Freinkman E, Dhawan A, Majumder B, Mondal J, Pinkerton AB, Eton E, Medhi R, Chandrasekar V, Rahman MM, Ichimura T, Gopinath KS, Majumder P, Kohandel M, Sengupta S. Targeting Tumor Phenotypic Plasticity and Metabolic Remodeling in Adaptive Cross-Drug Tolerance. Science Signaling. 2019 Aug 20;12(595). pii: eaas8779. doi: 10.1126/scisignal.aas8779. *Co-Corresponding author. ISSUE COVER




Kumar N, Prasad P, Jash E, Saini M, Husain A, Sehrawat S*, Goldman A*. Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment. 2018 Feb7. Mol Cell Biochem. doi: 10.1007/s11010-018-3294-z. *Co-corresponding author

Kumar N, Prasad P, Jash E, Jayasundar S, Singh I, Alam N, Murmu N, Somashekhar S, Sehrawat S*, Goldman A*. cAMP Regulated EPAC1 Supports Microvascular Density, Angiogenic and Metastatic Properties in a Model of Triple Negative Breast Cancer. Carcinogenesis. 2018 Jul 5. doi: 10.1093/carcin/bgy090. [Epub ahead of print]. *Co-corresponding author

Raza M, Prasad P, Gupta P, Kumar N, Sharma T, Rana M, Sehrawat S*, Goldman A*. Perspectives on the role of brain cellular players in cancer-associated brain metastasis: translational approach to understand molecular mechanism of tumor progression. Cancer Metastasis Rev. 2018 Oct 4. doi: 10.1007/s10555-018-9766-5. [Epub ahead of print] Review. *Co-corresponding author

Kaushansky A, Hedstrom L, Goldman A, Singh J, Yang P, Rathod P, Cynamon M, Wodarz D, Mahadevan D, Tomaras A, Navia A, Schiffer C. A call to arms: Unifying the fight against resistance. Science Signal. 23 Oct, 2018. Vol 11, Issue 553

Goldman, A. Drug-induced resistance: nipping it in the ‘budding’. Oncotarget. News and Views. November, 2018.

Jash E, Prasad P, Kumar N, Sharma T, Sehrawat S*, Goldman A*. Perspective on nanochannels as cellular mediators in different disease conditions. Cell Commun Signal. 2018 Nov 8;16(1):76. doi: 10.1186/s12964-018-0281-7. Review. *Co-corresponding author


Goldman A, Kohandel M, Clairambault J. Integrating Biological and Mathematical Models to Explain and Overcome Drug Resistance in Cancer, Part 1: Biological Facts and Studies in Drug Resistance. Current Stem Cell Reports, 2017Volume 3, Issue 3, pp 253–259, September 2017. REVIEW ARTICLE

Goldman A, Kohandel M, Clairambault J. The Math Behind Cancer Therapy Resistance: Integrating Biological and Mathematical Models to Explain and Overcome Drug Resistance, Part 2:  From theoretical biology motivations to mathematical models in cancer. Current Stem Cell Reports, Volume 3, Issue 3, pp 260–268, September 2017. REVIEW ARTICLE

Dhandapani M, Goldman A.  Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools. J. Mol. Bio. & Diag.2017 Sep;8(5). pii: 356. doi: 10.4172/2155-9929.1000356. Epub 2017 Jun 30.

Maciejko L, Smalley M, Goldman A. Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches. J. Mol. Bio. & Diag., 2017 Sep;8(5). pii: 350. doi: 10.4172/2155-9929.1000350. Epub 2017 Jun 28.


Kulkarni A, Rao P, Natarajan S, Goldman A, Sabbisetti S, Khater Y, Korimerla N, Sengupta S. A reporter nanoparticle that monitors its anticancer efficacy in real time. Proc Natl Acad Sci U S A. 2016 Mar 29. pii: 201603455.

Boareto M, Jolly M, Goldman A, Mani SA, Onuchic J, Ben-Jacob E. Notch-Jagged signaling can give rise to clusters of cells in a hybrid epithelial/mesenchymal phenotype. J R Soc Interface. 2016 May;13(118). pii: 20151106. doi: 10.1098/rsif.2015.1106.

Goldman A˦, Molavian H˦, Kohandel M, Phipps C, Wouters B, Sengupta S, Sivaloganathan S. Drug-induced reactive oxygen species (ROS) rely on cell membrane properties to exert anticancer effects. In Press, Scientific Reports, 2016 Jun 9;6:27439. doi: 10.1038/srep27439.˦Co-first authorship.

Goldman A, Kulkarni A, Kohandel M, Natarajan S, Pandi P, Ravi S, Sengupta S. Rationally designed 2-in-1 nanoparticles can overcome adaptive resistance in cancer. ACS Nano, 2016 Jun 28;10(6):5823-34. doi: 10.1021/acsnano.6b00320. Epub 2016 Jun 13.

Kulkarni A, Pandey P, Rao P, Mahmoud A, Goldman A, Sabbisetti S, Wyant G, Parcha S, Kotamraju V, Natarajan S, Chandrasekar V, Dinulescu D, Ruoslahti E, Roy S, Sengupta S. Computationally designed evolution-inspired supramolecular therapeutics for increased anticancer efficacy. ACS Nano. 2016 Jun 28;10(6):5823-34. doi: 10.1021/acsnano.6b00320.

Calibisi G, Guven S, Goldman A, Foygel, K, Chen P, Sengupta S, Baskin Y, Demirici U. Dynamic Microenvironment Induces Phenotypic Plasticity of Esophageal Cancer Cells Under Flow. Scientific Reports. 2016 Dec 2;6:38221. doi: 10.1038/srep38221.


*Goldman A, Tailoring combinatorial cancer therapies to target the origins of adaptive resistance. Molecular and Cellular Oncology 2015 Apr 14;3(1):e1030534. doi: 10.1080/23723556.2015.1030534 *Corresponding author.

Kulkarni A, Roy B, Rao P, Wyant G, Mahmoud M, Sengupta P, Goldman A, et al. Supramolecular nanoparticle exhibits enhancing antitumor efficacy via temporal inhibition of PI3K. Cancer Research, 2013 Dec 1;73(23):6987-97.

Pandey A, Kulkarni A, Goldman A, Roy B, Sarangi S, Sengupta P, Phipps C, Kopparam J, Oh M, Basu S, Kohandel M, Sengupta S. Mathematically modeling the sequential application of a cytotoxic nanoparticle and a PI3K-inhibitor enhances anti-tumor efficacy. Cancer Research, 2014 Feb 1;74(3):675-85.

*Goldman A, Majumder B, Kulkarni A, Ravi S, Goldman D, Majumder P, Sengupta S. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nature Communications, 2015 Feb 11;6:6139. doi: 10.1038/ncomms7139. *Corresponding author.


Rajagopal S, Meyer SC, Goldman A, Zhou M, Ghosh I. Minimalist Approach toward Protein Recognition by Epitope Transfer from Functionally Evolved -Sheet Surfaces. J. Am. Chem. Soc.; 2006; 128(44); 14356-14363. PMID:17076509

Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene. 2008 Jul 10;27(30):4210-20. PMID: 18345031

Goldman A, Condon A, Adler E, Tome M, Bernstein H, Dvorak K. Protective effects of glycoursodeoxycholic acid in Barrett’s esophagus cells. Dis Esophagus. 2010 Feb 1;23(2):83-93. PMID: 19549210

Goldman A, Shahidullah M, Goldman D, Khailova L, Watts G, Delamere N, Dvorak K. A novel mechanism of acid and bile acid-induced DNA damage involving Na+/H+ exchanger: Implication for Barrett’s esophagus. Gut. 2010 Dec;59(12):1606-16. PMID: 20876775.

Goldman A, Chen H, Roesly H, Tome M, Khailova L, Dvorak B, Bernstein H, Dvorak K. Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett’s esophagus pathogenesis. Am J Physiol Gastro Liver Physiol. 2011 Feb;300(2):G292-302. PMID: 21127259

Goldman A, Chen H, Khan MR, Roesly H, Hill KA, et al. (2011) The Na+/H+ Exchanger Controls Deoxycholic Acid-Induced Apoptosis by a H+-Activated, Na+-Dependent Ionic Shift in Esophageal Cells. PLoS ONE August 22, 2011, 6(8): e23835. doi:10.1371 PMID: 21887327

Saunders MD, Nieponice A, Dvorak K, Goldman A, Diaz-Cervantes E, De-la-Torre-Bravo A, Sobrino-Cossio S, Torres-Durazo E, Martínez-Carrillo O, Gamboa-Robles J, Upton M, Appelman HD, Bonavina L, Rothstein RI, Velanovich V. Barrett’s esophagus: endoscopic treatments I. Ann N Y Acad Sci. 2011 Sep;1232:140-55. doi: 10.1111/j.1749-6632.2011.06049.x.  REVIEW

Shields HM, Nardone G, Zhao J, Wang W, Xing Z, Fang D, Jacobson BC, Romero Y, Dvorak K, Goldman A, Pellegrini CA, Wiley EL, Peura DA, Tatum RP, Schnell TG. Barrett’s esophagus: prevalence and incidence of adenocarcinoma. Ann N Y Acad Sci. 2011 Sep;1232:230-47. doi: 10.1111/j.1749-6632.2011.06054.x. REVIEW

Dvorak K, Goldman A, Kong J, Lynch JP, Hutchinson L, Houghton JM, Chen H, Chen X, Krishnadath KK, Westra WM.  Molecular mechanisms of Barrett’s esophagus and adenocarcinoma. Ann N Y Acad Sci. 2011 Sep;1232:381-91. REVIEW

Richter JE, Penagini R, Pohl D, Dvorak K, Goldman A, Savarino E, Zentilin P, Savarino V, Watson JT, Wong RK, Pace F, Casini V, Peura DA, Herzig SJ, Kamiya T, Pelosini I, Scarpignato C, Armstrong D, DeVault KR, Bechi P, Taddei A, Freschi G, Ringressi MN, Degli’Innocenti DR, Castiglione F, Masini E, Hunt RH. Barrett’s esophagus: proton pump inhibitors and chemoprevention II. Ann N Y Acad Sci. 2011 Sep;1232:114-39. doi: 10.1111/j.1749-6632.2011.06048.x. REVIEW

Triadafilopoulos G, Taddei A, Bechi P, Freschi G, Ringressi MN, Degli’Innocenti DR, Castiglione F, Masini E, Majewski M, Wallner G, Sarosiek J, Dillon JF, McCallum RC, Dvorak K, Goldman A, Woodland P, Sifrim D, Richter JE, Vieth M, Neumann H, Langner C, Ishimura N, Amano Y, Felix VN. Barrett’s esophagus: proton pump inhibitors and chemoprevention I. Ann N Y Acad Sci. 2011 Sep;1232:93-113. doi: 10.1111/j.1749-6632.2011.06047.x. REVIEW

Falk GW, Jacobson BC, Riddell RH, Rubenstein JH, El-Zimaity H, Drewes AM, Roark KS, Sontag SJ, Schnell TG, Leya J, Chejfec G, Richter JE, Jenkins G, Goldman A, Dvorak K, Nardone G. Barrett’s esophagus: prevalence-incidence and etiology-origins. Ann N Y Acad Sci. 2011 Sep;1232:1-17. doi: 10.1111/j.1749-6632.2011.06042.x. REVIEW



“A Game of Clones: Multidisciplinary science elucidates the challenge of intratumor heterogeneity in non-small cell lung cancer” Precision World Lung Cancer Summit, Wyndham Beacon Hill, Boston MA. October, 2019. Invited speaker

“In-vitro and in-vivo models for cancer immunotherapy”. World Pharma Week, Seaport World Trade Center, Boston MA. June, 2019. Invited Organizer/speaker for Short Course

“Tumor Organoid and Ex-Vivo Models to Translate Oncolytic Viruses to the Clinic”. World Pharma Week, Seaport World Trade Center, Boston MA. June, 2019. Invited Speaker

“Translational Utility of an Ex-Vivo Human Tumor Model to Study Oncolytic Viruses in Glioblastoma Multiforme”. XHub, Seaport World Trade Center, Boston MA. May, 2019. Invited Speaker

“Math in Medicine: from drug resistance to personalized immuno-oncology”. Physical Sciences Oncology Center (PSOC) Seminar Series. Moffitt Cancer Center, Tampa FL. December, 2018. Invited Speaker

“Bioengineering platforms for personalized cancer medicine”. MRS Fall Meeting. Sheraton, Boston, MA. November, 2018. Invited Speaker

“Drug Resistance and the Tumor-Immune Microenvironment”. Cancer Biology Grand Rounds. University of Arizona Cancer Center. Tucson, AZ. October, 2018. Invited Speaker

“Emerging Technologies for Personalizing Cancer Immunotherapy”. Discovery on Target. Boston Marriot, Downtown. Boston, MA. September, 2018. Invited Speaker

“Using Mass Spectrometry to Profile the Tumor-Immune Landscape, ex-vivo”. American Association for Cancer Research (AACR) Annual Meeting. April, 2018. Chicago, IL. Invited Speaker

“Profiling Cancer Immunotherapy Using a Patient-Derived ex-vivo Platform”. ICTO. February, 2018. Berlin, Germany. Invited Speaker


“Drug Resistance and the Role of the Tumor Microenvironment”. Arizona Cancer Center, Radiation Oncology Seminar Series. University of Arizona, Tucson AZ. February, 2017. Invited Speaker.

“The Tumor Microenvironment and Drug Resistance”. Invited Seminar, Division of Pathology, Roche Diagnostics. Tucson, AZ. February 2017. Invited speaker

“Pre-Clinical Models for Immuno-Oncology Drug Discovery”. CBI Immuno-Oncology Summit. Boston, MA. May 2017. Invited Speaker

“Harness the Tumor Microenvironment to Advance Immunotherapy Development.” CBI Immuno-Oncology Summit. Boston, MA. May 2017. Invited Speaker

“Pre-clinical Ex-Vivo Model to Predict Cancer Immunotherapy Efficacy”. Precision Medicine Symposium 2017. Boston, MA. Invited Speaker.


“Overcoming Drug resistance to improve the outcome of cancer therapy” Strides Against Breast Cancer, Boston MA Park Plaza Hotel. American Cancer Society. August, 2015. Invited speaker

“When Math Saves Lives”. Discover Brigham. Brigham and women’s hospital, Boston MA. October, 2015. Invited speaker  

“Understanding tumor heterogeneity using bioengineering approaches”. Moffitt Cancer Center, department of mathematical oncology seminar series. February, 2016. Invited speaker

“Bioengineering ourselves out of drug resistance: The consequence of tumor heterogeneity”. Fields Institute, Math Oncology VI Workshop, University of Toronto. April, 2016. Invited speaker

 “Multi-drug symbiosis enabled through dynamic metabolic behavior” Gordon Conference on drug resistance. Biddeford, ME. June, 2016. Invited short talk


“Mechanistic insights into adaptive chemoresistance driven by dynamic tumor heterogeneity.” CNIO and nature conference on tumor Heterogeneity and cell plasticity, Madrid Spain. October 2013 Invited speaker.

 “Strategies to target cancer therapy resistance and tumor heterogeneity.” Hackensack Cancer Center, New Jersey. June 2014 (Cancer Center sponsored event) Invited speaker.

“Mathematical modeling chemotherapy induced tumor heterogeneity.” Workshop on Mathematical Modeling Oncology V: Heterogeneity and Plasticity in Cancer.  Invited speaker, sponsored by University of Toronto, Toronto Canada. May, 2014

“Adaptive drug resistance as a consequence of deterministic tumor heterogeneity”. Gordon Conference on Drug resistance. Bethel, ME. July, 2014. Abstract poster and invited speaker